Clinical Report: Diagnostic Efficacy of MAPIA for Neurocysticercosis Antibody Detection
Overview
The Multiantigen Print ImmunoAssay (MAPIA) using three recombinant/synthetic antigens demonstrated high sensitivity (97.7%) and specificity (97.4%) for antibody detection in neurocysticercosis (NCC). MAPIA showed comparable performance to the gold standard LLGP-EITB assay, with 100% sensitivity in subarachnoid NCC and cases with >5 cysts.
Background
Neurocysticercosis (NCC) is a leading cause of seizures worldwide, caused by Taenia solium larvae infecting the central nervous system. Diagnosis relies primarily on neuroimaging, which is often unavailable in resource-limited settings. Serological antibody detection supports diagnosis, with the LLGP-EITB assay considered the gold standard due to its high sensitivity and specificity. However, LLGP-EITB requires parasite-derived antigens and complex laboratory infrastructure, limiting accessibility. Recombinant antigen-based assays like MAPIA offer a simpler, cost-effective alternative.
Data Highlights
NCC Group
Sample Size
MAPIA Sensitivity (%)
Subarachnoid NCC
73
100
>5 Parenchymal Cysts
72
100
3–5 Parenchymal Cysts
59
96.6
1–2 Parenchymal Cysts
95
94.7
Healthy Controls
77
Specificity 97.4
Key Findings
MAPIA achieved an overall sensitivity of 97.7% and specificity of 97.4% for NCC antibody detection.
Sensitivity was 100% for subarachnoid NCC and parenchymal NCC with more than 5 cysts.
Sensitivity slightly decreased in cases with fewer cysts: 96.6% for 3–5 cysts and 94.7% for 1–2 cysts.
MAPIA showed 98.33% agreement with the LLGP-EITB assay, the current serological gold standard.
The assay uses three recombinant/synthetic antigens (rGP50, rT24H, sTs14) representing principal antigenic families, eliminating the need for parasite-derived materials.
MAPIA is simpler, reproducible, and more accessible for low-resource settings compared to LLGP-EITB.
Clinical Implications
MAPIA provides a reliable and accessible serological tool for NCC diagnosis, particularly valuable in resource-limited settings lacking advanced imaging or complex laboratory capacity. Its high sensitivity in severe NCC forms supports its use for case confirmation and epidemiological studies. Adoption of MAPIA could improve diagnostic coverage and timely management of NCC worldwide.
Conclusion
The MAPIA assay offers a simpler, cost-effective alternative to the LLGP-EITB for antibody detection in neurocysticercosis, with comparable diagnostic accuracy. This innovation has the potential to enhance NCC diagnosis accessibility globally.
References
Garcia et al. 2023 -- Evaluating the Diagnostic Efficacy of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Identification in Human Neurocysticercosis
by Luz M Toribio, Carolina Guzman, Alessandra Vasquez, Herbert Saavedra, Isidro Gonzales, Javier A Bustos, Hector H García, for the Cysticercosis Working Group in Peru
